Once-weekly Fluoxetine
Once-weekly Fluoxetine
复制标题
DOI：
10.2165/00003495-200161150-00006
复制
发表时间：
2001-01-01
期刊：
影响因子：
11.5
通讯作者：
Goa, KL
中科院分区：
文献类型：
--
作者：
Wagstaff, AJ;Goa, KL
选择性5 -羟色胺再摄取抑制剂氟西汀的相对较长的半衰期使得一种延迟释放（肠溶）制剂的开发成为可能，每粒胶囊含有90毫克氟西汀，每周口服一次。改用每周一次氟西汀90mg，持续25周的患者的累积复发率（在接受13周氟西汀20mg /天治疗后）与继续接受氟西汀20mg /天治疗的患者相似，显著低于改用安慰剂的患者。在其他评估参数（改良的17项汉密尔顿抑郁评定量表、临床总体印象-疾病严重程度量表）上，每周一次的治疗效果也与每日一次的治疗效果相似。在接受4周氟西汀20mg /天治疗后，可评估患者每周接受一次氟西汀90mg治疗，持续12周，患者依从性（使用电子监测片剂瓶测量）从基线85.4%维持在87.5%；相比之下，持续接受20mg /天治疗12周的患者的依从性显著下降（从基线时的87.3%降至79.4%,p < 0.001）。每周一次的氟西汀耐受性良好，耐受性与速释制剂相似。
The relatively long half-life of the selective serotonin reuptake inhibitor fluoxetine has allowed the development of a delayed-release (enteric-coated) formulation containing 90 mg fluoxetine per capsule for once-weekly oral administration.The cumulative relapse rate in patients switched to once-weekly fluoxetine 90 mg for 25 weeks (after responding to 13 weeks of fluoxetine 20 mg/day) was similar to that in patients continuing to receive fluoxetine 20 mg/day and significantly lower than seen in patients switched to placebo.The efficacy of the once-weekly formulation was also similar to that of the daily formulation in other assessment parameters (modified 17-item Hamilton Rating Scale for Depression, Clinical Global Impressions - Severity of Illness Scale).Patient compliance (measured using an electronically monitored tablet bottle) was maintained at 87.5% in evaluable patients receiving once-weekly fluoxetine 90 mg for 12 weeks from a baseline of 85.4% after responding to 4 weeks of fluoxetine 20 mg/day; in contrast, compliance declined significantly (from 87.3% at baseline to 79.4%; p < 0.001) in patients continuing to receive 20 mg/day for 12 weeks.Once-weekly fluoxetine is well tolerated, with a tolerability profile similar to that of the immediate-release formulation.